Clinical chemistry and post-liver-transplant monitoring.
Liver transplantation is an accepted therapy for end-stage liver disease. After allografting, a variety of clinical problems may require laboratory involvement for accurate and timely diagnosis and intervention. Critical factors in the choice of a laboratory test menu to support a transplant program include turnaround times that support clinical decisionmaking, real diagnostic value, and real value for money. Particular clinical problems, whose early presentation must be anticipated, include graft ischemia, primary nonfunction, and hepatic artery thrombosis. Acute rejection is common at 5-10 days posttransplantation, the principal target being the biliary tree. Longer-term problems are associated with the therapeutic drug measurement of cyclosporin A and, increasingly, tacrolimus (FK506); the side effects of immunosuppressant therapy also require monitoring. A successful liver transplant program can be adequately supported with a simple battery of automated tests that are cheap, fast, and available at all times.
Hickman
P E
PE
Department of Chemical Pathology, Queensland Liver Transplant Service, Princess Alexandra Hospital, Woolloongabba, Australia. PHickman@gpo.pa.uq.edu.au
Potter
J M
JM
Pesce
A J
AJ
D015415:Biomarkers / Q000097:blood; D002624:Chemistry, Clinical; D016572:Cyclosporine / Q000493:pharmacokinetics / Q000627:therapeutic use; D016903:Drug Monitoring; D006084:Graft Rejection / Q000097:blood / Q000175:diagnosis; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology / Q000502:physiology*; D008213:Lymphocyte Activation; D015166:Monitoring, Immunologic; D008991:Monitoring, Physiologic / Q000379:methods*; D016559:Tacrolimus / Q000493:pharmacokinetics / Q000627:therapeutic use
D015415:Biomarkers; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus